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Background: Irrespective of the underlying aetiology, 90% of hepatocellular carcinomas arise and progress on a background of
chronic inflammation. We have explored the independent prognostic value of circulating inflammatory cells.
Methods: Peripheral blood count data sets from 583 consecutive patients presenting to a single UK centre (2000–2010) were
analysed for associations with tumour stage, liver function, performance status (PST) and survival. Validation was in an independent
Hong Kong cohort (585 patients; 2007–2013).
Results: In both UK and Hong Kong cohorts, neutrophils, platelets, lymphocytes, the neutrophil/lymphocyte ratio (NLR) and the
Systemic Immune-Inflammation Index (SII) correlated stepwise, either increasing or decreasing (lymphocytes), with tumour node
metastasis (TNM) and Childs–Pugh stage, PST and consequently with the combined Barcelona Clinic for Liver Cancer stage.
Survival analyses confirmed the NLR and SII as highly significant prognostic biomarkers. Focused on individual cell types, only the
neutrophil count was independently associated with both TNM stage and PST, as well as being significantly and independently
associated with poorer survival.
Conclusions: In this study of 1168 patients, neutrophils alone, rather than lymphocytes or platelets, were independently associated
with outcome. These data support further characterisation of a potentially distinctive role for neutrophils as facilitators of tumour
progression and deteriorating performance.
Hepatocellular carcinoma (HCC) has the second highest cancer-
related mortality worldwide (International Agency for Research on
Cancer, 2014), reflecting its rising incidence, late-stage
presentation and limited therapeutic options. Globally, HCC most
commonly arises in individuals with underlying chronic liver
diseases (CLDs) caused by hepatitis B virus (HBV) or hepatitis C
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virus. In the UK, where the prevalence of these infections is
relatively low, HCC was the ninth commonest cause of cancer
mortality in 2014, accounting for 5091 deaths (Cancer Research
UK, 2017). Of growing concern, although deaths from other
cancers are falling in the UK, HCC-related mortality is rising,
having doubled over the last decade. The reasons include a
worrying rise in alcohol-related liver disease (ARLD) (Williams
et al, 2014), but also a dramatic increase in the prevalence of
obesity and type 2 diabetes mellitus-related non-alcoholic fatty
liver (NAFLD) (Dyson et al, 2014). Driven by stage, potentially
curative treatments (resection, transplantation and ablation) are
offered to o15% of patients with HCC. Although first-line
palliative locoregional therapy and the multikinase inhibitor
sorafenib (Llovet et al, 2008) are increasingly used, owing to
impaired liver function or deteriorating performance status (PST),
up to 50% of those affected are offered supportive care only and
overall survival is poor (Dyson et al, 2014). The recent failures of
targeted second line agents in phase III trials offer limited hope for
change, the lack of progress being attributed to a failure to identify
the key drivers of hepatocarcinogenesis, as well as the lack of
biomarkers guiding stratification of therapy (Llovet et al, 2016).
Molecular aberrations in the tumour cells are undoubtedly
oncogenic drivers in HCC (Hoshida et al, 2009; Nault et al, 2013;
Schulze et al, 2015; Villanueva et al, 2015; Zucman-Rossi et al,
2015), but interactions with inflammatory cells within the tumour
microenvironment may also be key (Hanahan and Weinberg,
2011). Inflammation is a cardinal feature of progressive liver
disease and predisposition to HCC, the latter attributed in part to
inflammatory cell generated oxidative stress and DNA damage. In
addition, however, an inflammatory response associated with a
cancer can either aid its elimination or drive its progression. The
presence of tumour-infiltrating lymphocytes in HCC resections is
associated with better survival (Chew et al, 2010), although
cumulative evidence from murine and human studies recognises a
balance between the pro-tumour vs antitumour effects of different
lymphocyte subsets, including regulatory CD4 and cytotoxic CD8
lymphocytes (Gooden et al, 2011). Similarly, for other immune
cells, such as macrophages and neutrophils, recognition of pro-
tumour and anti-tumour subtypes (Hernandez-Gea et al, 2013)
and the role of platelets is growing (Carr and Guerra, 2013). The
present therapeutic focus is on immune checkpoint inhibitors, a
class of drugs which promotes the CD8 anti-tumour response.
Although Phase III studies in patients with HCC are awaited, data
from early phase trials suggests that this approach may offer a
significant survival advantage for some patients (Kudo, 2015). How
to identify patients that will respond to checkpoint inhibition is as
yet unknown and the lack of routine diagnostic biopsy for HCC –
owing to good diagnostic performance of contrast enhanced cross
sectional imaging combined with the small risks of haemorrhage
and tumour seeding in patients with cirrhosis (Sherman and Bruix,
2015) – hampers the development of clinically relevant biomarkers
(Torbenson and Schirmacher, 2015) for these and other therapies.
Monitoring tumour responses can also be challenging.
Given the difficulties acquiring liver tissues, circulating
biomarkers that accurately reflect the tumour microenvironment
are needed and in parallel to the research focused on the localised
tumour immune response, a number of studies exploring
circulating inflammatory biomarkers – which potentially have
prognostic or clinically relevant predictive value – have been
reported in patients with HCC. Largely restricted to smaller studies
in treatment subgroups, most often in patients with underlying
viral hepatitis, an elevated neutrophil to lymphocyte ratio (NLR),
reflecting either increases in neutrophils or reduced lymphocytes
(Xu et al, 2014), reportedly has prognostic value post resection
(Gomez et al, 2008), liver transplantation (Limaye et al, 2013) and
ablation (Dan et al, 2013). Recently the Systemic Immune-
Inflammation Index (SII) score – based on numbers of neutrophils,
lymphocytes and platelets (Hu et al, 2014) – has been proposed as
an alternative.
We have interrogated peripheral inflammatory cell counts in
two large patient cohorts (583 and 585 patients), wanting to
explore the relative biological contributions of neutrophils,
lymphocytes and platelets in a more comprehensive fashion –
across all HCC stages, underlying aetiologies and treatment
subsets. Searching for driving influences, our aim was to further
understand their associations with HCC progression.
MATERIALS AND METHODS
Patient cohorts. We have assessed standard blood count data in
two patient cohorts. Cohort 1 included patients previously
described (Dyson et al, 2014). Briefly, these were consecutive
patients managed by the Newcastle HCC multidisciplinary meeting
between the years 2000 and 2010, guided by internationally
accepted guidelines (Bruix et al, 2001), including the Barcelona
Clinic for Liver Cancer (BCLC) staging algorithm (Llovet et al,
2004; Bruix and Sherman, 2005). Tumour node metastasis (TNM),
Childs-Pugh (CP) and BCLC stages were documented, as were
demographic and clinical parameters, Eastern Cooperative Oncol-
ogy Group (ECOG) PST, treatments and survival. The study was
registered with the hospital trust audit department and cases were
followed until 31 March 2017, defining a minimum period of 6
years post diagnosis. Blood cell counts, including platelets,
neutrophils and lymphocyte data at the time of diagnosis and
staging were obtained retrospectively from patients’ electronic
records. Of 632 consecutive patients with HCC, 49 cases were
excluded as complete full blood count data were unavailable,
leaving 583 included Newcastle patients. The SII index was
calculated as SII¼ P  N/L, where P, N and L were the peripheral
platelet, neutrophil and lymphocyte counts, respectively (Hu et al,
2014).
The Newcastle patient data set was used as the exploratory
cohort, investigating relationships between circulating immune
cells and scores with clinical parameters and outcomes. A second
cohort of consecutive HCC patients (n¼ 585) was used for
validation purposes. The cohort consisted of HCC patients
presenting to the Prince of Wales Hospital in Hong Kong between
1 July 2007 and 31 July 2013 (Chan et al, 2012, 2017), also followed
until 31 March 2017. The construction of this cohort was approved
by the Joint Chinese University of Hong Kong – New Territories
East Cluster Research Ethics Committee.
Statistical analyses. All statistical analyses were done with SPSS
for Windows, version 22 (SPSS Inc., Chicago, IL, USA), licensed to
Newcastle University. Figures were drawn using GraphPad Prism 6
(GraphPad Inc., La Jolla, CA, USA). Differences between
categorical variables were assessed by Pearson’s w2-test. Differences
between groups of continuous variables that were non-parame-
trically distributed were assessed using Mann–Whitney or
Kruskal–Wallis tests. Bivariate correlations were evaluated using
Spearman’s rank correlation coefficient. For categorical data,
multinomial regression was used to assess the independent
associations of multiple variables. A P-value of o0.05 was
considered significant. Survival was recorded as months from
diagnosis to 31 March 2017. Differences in cumulative survival
were determined using the Kaplan–Meier method and a log-rank
test. The Cox proportional hazards regression model was used to
identify parameters associated with survival. Factors initially
considered by univariate analysis included age, gender, associated
aetiology, presence cirrhosis, number of tumours, size of largest
tumour, presence of extrahepatic disease or portal vein invasion/
thrombosis, presence of ascites or encephalopathy, serum
a-fetoprotein (AFP), serum albumin, serum bilirubin, prothrombin
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time, whole blood count platelets, neutrophils, lymphocytes, as well
as the presence of constitutional symptoms. A cutoff of Po0.05
was used to select variables entered into the multivariate model.
RESULTS
Differences and similarities between the Newcastle and Hong
Kong cohorts. The demographics of the Newcastle and Hong
Kong cohorts of patients with HCC are compared and contrasted
in Table 1, alongside the combined cohort of 1168 patients. Similar
numbers of patients were studied, but in Newcastle these reflected
patients presenting over an 11 year period, compared with 5.5
years in Hong Kong. The Newcastle cohort median age was
significantly greater, at 69 vs 60 years, and included more women.
In addition, there were striking differences in underlying liver
disease aetiology, with the majority of HCC arising on a
background of fatty liver disease in the Newcastle cohort, vs
HBV in the Hong Kong cohort. A greater proportion of Newcastle
patients had no evidence of underlying CLD of any kind. Despite
this, a greater number of Hong Kong patients developed HCC in
the absence of cirrhosis – as is commonly recognised in the
presence of chronic HBV infection. Notably, the average tumour
size and TNM stage were more advanced in the Hong Kong
cohort. While a greater proportion in Hong Kong had extrahepatic
disease and portal vein invasion, which contribute to stage BCLC
C/D classifications – a greater proportion of Newcastle patients
were classed as BCLC stage D, reflecting more Newcastle cases
staged as ECOG PST 3 or 4 and/or liver function CP C. Peripheral
blood cell count data is also summarised in Table 1. Although there
were no differences in mean neutrophil or platelet counts, the
mean lymphocyte count in the Hong Kong Cohort was slightly but
significantly lower than the Newcastle cohort, with consequently
higher NLR and SII. The primary surgical treatment in Newcastle
was orthotopic liver transplantation, whereas in Hong Kong Prince
of Wales Hospital it was resection. Newcastle patients with
intermediate stage disease were more likely to receive loco-regional
therapy, compared with Sorafenib in the Hong Kong cohort –
reflecting the greater numbers in Hong Kong with extrahepatic
disease/TNM IV at presentation, but also the temporal differences
in the cohorts and the availability of Sorafenib at the time of
patient presentation.
Consequent to the mostly advanced stages at presentation as
well as limited therapeutic options as previously described,
irrespective of the centre and cohort differences, very similar
numbers of patients (41% and 38%, respectively) received
supportive care only. Despite the differences between the cohorts,
this similarity was possibly the most telling, as there was no
significant survival difference between the two. Median survival in
the Newcastle cohort was 11.9 months compared with 8.4 months
in Hong Kong (Kaplan–Meier, P¼ 0.219).
Neutrophils and platelets rise with advanced tumour stage,
whereas lymphocytes fall. In both the Newcastle and Hong Kong
cohorts, the NLR and the SII rose in association with advancing
TNM, CP and PST, as well as with the BCLC stage, which
combines the three. Focusing on the different cell types rather than
combination scores, significant incremental increases in median
neutrophil count paralleled increases in TNM and PST. Con-
versely, lymphocytes tended to fall with advancing stages. Platelets
fell significantly with advancing CP stage, but increased in
association with TNM and BCLC stage. Figures for Newcastle
and Hong Kong cohorts independently are shown in
Supplementary Figures 1–4, whereas the combined cohort data
summarising changes with TNM, CP and PST is presented in
Figures 1–3.
As each of these cell counts can decline in patients with cirrhosis
and portal hypertension, which are both drivers of advancing CP
and BCLC stage, cirrhosis as a potential confounder was
considered. Each of the cell counts, platelets most notably,
correlated negatively with the presence of cirrhosis (Spearman’s
bivariate correlations: neutrophils  0.244, Po0.001; lymphocytes
 0.093, P¼ 0.001; platelets  0.426, Po0.001). Restricting the
assessment of associations of the cell types with the different
staging systems to patients without cirrhosis (403 patients), the
patterns of change and their significance were similar to those
described above (data not shown). The only difference was a lack
of a significant association between platelets and CP stage.
The stepwise increases in median neutrophil counts with PST as
shown in Figure 3 were interesting and although hard to dissociate
from advancing cancer stage, the relationship between neutrophils
and PST persisted (Po0.001) in a multinomial regression analysis,
which included other factors significantly associated with PST in a
univariate analysis (peripheral lymphocyte and platelet counts,
but also age, sex, aetiology, cirrhosis, tumour number, tumour
size, vascular invasion, extrahepatic disease, ascites, prothrombin
time, serum albumin, bilirubin, AFP and Newcastle vs Hong Kong
cohorts). Data are shown in Supplementary Table 1, where
variables at each ECOG PST stage were compared with the last
and most advanced stage (Stages 3 and 4 combined). Although
age, tumour factors (size, vascular invasion and extrahepatic
disease) and liver function features (ascites) were significantly
associated compared with ECOG PST 0, only falling serum
albumin and rising neutrophil count were incrementally and
significantly associated at each stage ECOG PST stage. Neither
lymphocyte nor platelet count associations were independently
significant.
The prognostic value of the NLR. A number of previous studies
have explored the NLR in patients with HCC. An NLR of X5 vs
o5 was shown to be a poor prognostic indicator in a cohort of 96
patients undergoing resection (Gomez et al, 2008), as well as in a
cohort of 160 patients treated with liver transplantation (Limaye
et al, 2013). This cutoff value in fact performed poorly in our
combined cohort of 152 surgically treated patients, where only 20
had an NLR X5. Using a median cutoff value for our combined
surgical cohort of X2.5 vs o2.5 (Newcastle cases 41 vs 43; Hong
Kong cases 35 vs 33), there was again no significant difference in
either median or long term survival between the groups. The
majority of patients undergoing surgical treatment in our cohorts
(87%) had HCC classed as TNM stage I or II, without an obvious
difference in NLR between these stages of disease (Figure 1).
In patients with all stages of disease, however, the whole cohort
median NLR value of 3.15 was a very highly significant
discriminator by Kaplan–Meier analysis. Median survival in the
combined cohort (n¼ 578 o3.15; vs n¼ 588 X3.15) was 18.8
months vs 4.5 months (Po0.001, Kaplan–Meier, as shown in
Figure 4). In a multivariate Cox regression analysis, including other
variables significant in a univariate analysis (tumour number,
largest diameter, prothrombin time, albumin, bilirubin and AFP as
continuous variables; the presence of ascites, portal vein invasion,
extrahepatic disease, constitutional symptoms, underlying aetiol-
ogy and primary treatment group as categorical variables), an NLR
X3.15 was independently associated with poorer survival (hazard
ratio (HR) 0.71; 0.62–0.81; Po0.001).
The prognostic value of the SII. Recognising the potential
contribution of circulating platelets, with a particular interest in
the role they play in promoting circulating tumour cell survival and
metastases, Hu et al (2014) proposed the SII index as an alternative
and possibly more informative biomarker. To calculate the SII, the
NLR is multiplied by the platelet count. Hu et al (2014) used a
retrospective cohort of 133 resection patients to propose an SII
4330 109 as having poor prognostic value, which they validated
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in a prospective cohort of 123 patients. An SII 4300 showed
promise in our small transplanted cohort (n¼ 53), trending
towards significance (median survival 90.8 months (n¼ 31), vs
72.2 months (n¼ 22), for SII o300 or 4300, respectively,
P¼ 0.280). In our combined resection series (n¼ 99), however,
the trend was reversed (median survival 82.4 months (n¼ 33) vs
125.0 months (n¼ 66); P¼ 0.164). For these small groups of
surgically treated patients, therefore, we did not confirm a
prognostic value in terms of survival. In our entire combined
cohort, however, an SII4300 was present in 847 of 1168 patients,
associated with a median survival of 6.9 months compared with
21.9 months for those with an SII o300 (Po0.001, Kaplan–
Meier). The survival curves comparing patients below and above
the median SII of 569 (n¼ 582 vs 584) are shown in Figure 4 (18.9
months vs 4.4 months, Po0.001). In a multivariate Cox regression
analysis similar to that described for the NLR, a median SII above
Table 1. Patient cohorts
Newcastle cohort 01 January
2000–31 December 2010
Hong Kong cohort 01 January
2007–31 July 2013
P-value Combined cohort
Demographics
Sample size 583 585 1168
Age (median) (range) 69 (18–93) 60 (18–88) o0.001 65 (18–93)
Male/female (%) 473/110 (81.1/18.9) 516/69 (88.2/11.8) 0.008 989/179(84.7/15.3)
Tumour characteristics
Tumour number (median) 1 2 0.790 2
Tumour size (cm, median) 4.5 7.8 o0.001 6
Extrahepatic disease N/Y 489/94 452/133 0.004 820/348
Vascular invasion N/Y 430/153 390/195 0.008 941/227
Cirrhosis N/Y (%) 157/426 (26.9/73.1) 246/339 (42.1/57.9) o0.001 403/765 (34.5/65.5)
Aetiology of liver disease (% of
cohort)
ALD 168 (28.8) 0 o0.001 168 (14.4)
NAFLD 127 (21.8) 0 127 (10.9)
HBV 28 (4.8) 469 (80.2) 497 (42.5)
HCV 60 (10.3) 41 (7.1) 101 (8.7)
Haemachromatosis 31 (5.3) 0 31 (2.6)
AIH/PBC/PSC 27 (4.6) 0 27 (2.3)
Cryptogenic/other cirrhosis 28 (4.8) 36 (6.1) 64 (5.5)
No underlying CLD 114 (19.6) 39 (6.6) 153 (13.1)
ECOG PS
ECOG PS 0 217 186 o0.001 403
ECOG PS 1 160 365 525
ECOG PS 2 115 25 140
ECOG PS 3 78 9 87
ECOG PS 4 13 0 13
TNM
TNM I 214 24 0.001 238
TNM II 106 140 246
TNM IIIA or IIIB 168 82 250
TNM IV 95 339 434
Childs–Pugh
Childs–Pugh A 370 402 o0.001 772
Childs–Pugh B 133 156 289
Childs–Pugh C 80 27 107
BCLC stage
BCLC stage 0/A 88 94 o0.001 182
BCLC stage B 94 140 234
BCLC stage C 268 316 584
BCLC stage D 133 35 168
Peripheral cell counts
Neutrophils (mean±s.e.) 4.8±0.1 4.9±0.1 0.129 4.9±0.1
Lymphocytes (mean±s.e.) 1.5±0.0 1.3±0.0 o0.001 1.4±0.0
Platelets (mean±s.e.) 199±5.3 206±5.5 0.240 203±3.8
NLR (mean±s.e.) 4.1±0.2 4.9±0.2 o0.001 4.5±0.1
SII (mean±s.e.) 857±46 1113±63 o0.001 986±40
Primary treatment
Liver transplant 53 0 o0.001 53
Resection 31 68 99
Locoregional 253 168 421
Sorafenib 9 128 137
Supportive care 237 221 458
Median survival (months) 11.9 (10.2–13.6) 8.4 (6.8–10.1) 0.219 10 (8.7–11.3)
Abbreviations: AIH¼ autoimmune hepatitis; ARLD¼ alcohol-related liver disease; BCLC¼Barcelona Clinic for Liver Cancer; CLD¼ chronic liver disease; ECOG = Eastern Cooperative Oncology
Group; HBV¼ hepatitis B virus; HCV¼hepatitis C virus; NAFLD¼ non-alcoholic fatty liver disease; NLR¼ neutrophil lymphocyte ratio; N/Y¼ no/yes; PBC¼primary biliary cholangitis; PS¼
performance status; PSC¼primary sclerosing cholangitis; SII¼ Systemic Immune-Inflammation Index. The patient demographic data, disease aetiology, tumour characteristics, liver function
parameters, functional status and treatments administered are summarised for both Newcastle and Hong Kong Cohorts discretely, as well as for the combined cohort. Differences between the two
data sets were determined by Chi Square for categorical data, or Mann-Whitney test for continuous data. Cell count data are shown as a mean value representing  109 l 1.
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the median value was independently associated with poorer
survival (HR 0.70; 0.60–0.81, Po0.001).
In our combined cohort, both the NLR and the SII as
continuous variables correlated highly significantly with tumour
number, tumour size, vascular invasion, AFP and extrahepatic
disease. The stronger correlations were with the SII, in particular
with tumour size (0.498, Spearman’s correlation, Po0.001).
Exploration of the contributions of distinct inflammatory
cells. In the large combined cohort studied, including all stages
of disease and underlying aetiologies, we aimed to explore the
independent contributions and associations of the cell types, rather
than the combination scores. Focused on survival, univariate
analyses for the Newcastle cohort, the Hong Kong cohort and the
combined cohort, followed by multivariate Cox regression analysis
including those variables with a P-value o0.05, are shown in
Table 2. Variables independently significantly associated with
adverse survival in the Newcastle cohort, validated in the Hong
Kong cohort, included tumour factors (increased HCC number or
size and the presence of vascular invasion or extrahepatic disease),
falling serum albumin, rising bilirubin, the presence of constitu-
tional symptoms and a rising peripheral neutrophil count.
Additional factors in the Hong Kong cohort significantly
associated with adverse survival included the presence of ascites,
an elevated AFP, an elevated prothrombin time, as well as a lower
lymphocyte count. In the larger combined cohort, where there was
no significant difference in survival between the two cohorts,
independent significance persisted for serum AFP and the presence
of ascites, but not for the prothrombin time or lymphocyte count.
Notably, in both cohorts, the peripheral neutrophil count was the
only inflammatory cell count with independent prognostic value in
a multivariate Cox regression analysis including all variables with a
P-value o0.05. Treated as a categorical variable, taking the
neutrophil median value as the cutoff discriminating two groups of
patients (o4.2 vsX4.2), the difference in median survival was 17.3
vs 5.1 months (Kaplan–Meier; Po0.001, Figure 4), with similarly
independent significance (HR 0.77, 0.66–0.89; P¼ 0.001). The
survival curves for both lymphocytes and platelet counts, above
and below their median values, were significant by Kaplan–Meier
analyses, also shown in Figure 4. Again, neither was significant in a
multivariate analysis.
Exploring neutrophil associations with the other inflammatory
cells in the combined cohort, a positive and highly significant
correlation was noted with platelets (0.565, Po0.001). A much
weaker but still significant correlation was also observed with
lymphocytes (0.108, Po0.001). As described, the presence or
absence of cirrhosis had a significant impact on cell counts, with
median values (SI units  109 l 1) in the absence and presence of
cirrhosis being 5.0 vs 3.9; 246 vs 143; 1.6 vs 1.4 for neutrophils,
platelets and lymphocytes, respectively (Po0.001; Po0.001 and
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Figure 1. Inflammatory cells associations with TNM stage. Newcastle and Hong Kong data sets combined associations with advancing tumour
node metastasis (TNM) stage for neutrophil, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (Systemic Immune-
Inflammation Index) are shown. Statistical differences were assessed by Kruskal–Wallis test.
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P¼ 0.001 respectively, Mann–Whitney). Focused only on patients
without cirrhosis, the highly significant correlation between
neutrophils and platelets remained (Spearman’s 0.402, Po0.001),
whereas the weak association between neutrophils and lympho-
cytes was lost (Spearman 0.012, P¼ 0.805). Revisiting survival,
restricting analyses to patients without cirrhosis, neutrophils
remained the only circulating cell significantly and independently
associated with survival (data not shown).
DISCUSSION
Studying two large cohorts of patients with HCC from Newcastle
and Hong Kong has provided the opportunity to explore the
prognostic value of peripheral cell counts and combination scores
in much greater depth than before, as previous case series have
tended to be small and/or focused on specific treatment groups.
Including all patients presenting to our units over defined periods
of time has captured all stages of disease. Furthermore, the quite
marked differences between the Newcastle and Hong Kong cohorts
has facilitated a comprehensive assessment of the value of
combined scores, as well as the contributions of individual cell
types, which goes beyond the influence of important factors such as
age, sex, underlying aetiology of disease, geographical location,
presence or absence of cirrhosis and treatments received.
Circulating inflammatory cell counts and combined inflamma-
tory scores generally increased with more advanced TNM, CP and
BCLC stage, with the exception being lymphocytes, which were
inversely related. Notably, lymphocyte counts were slightly lower
in the Hong Kong cohort independently of stage and variance in
the systemic inflammatory response associated with geographical
location have been previously reported (Dolan et al, 2017). As
cirrhosis with portal hypertension has a very well established
impact on circulating cell counts, it was important to confirm that
the associations with advancing stage persisted even in the absence
of cirrhosis, supporting the influence of the advancing cancer on
these peripheral cell counts. The association of neutrophils with
PST was notable and persisted in a multinomial regression analysis
independently of other highly significantly associated factors. This
raises the possibility that elevated numbers of circulating
neutrophils may contribute to the cancer related cachexia
syndrome, of which declining PST is a critical part. Although
not well understood, an inflammatory tumour microenvironment
has a key role in the development of cancer related cachexia, with
neutrophil infiltration in association with elevated levels of
circulating neutrophils reported in animal studies (Chiba et al,
2014). Not only does PST have a major impact on cancer patients’
survival, it also impairs the capacity to withstand the anti-cancer
treatments that might prolong survival.
Turning to prognosis, in this study we have comprehensively
assessed the prognostic survival value of both the NLR and the SII.
Taken across all stages of disease in these large cohorts, rising
values undoubtedly have prognostic value, although their clinical
value within stages of disease and treatment categories remains
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Figure 2. Inflammatory cells associations with CP stage. Newcastle and Hong Kong data sets combined associations with advancing Childs-Pugh
(CP) stage for neutrophil, platelets and lymphocytes, as well as NLR (neutrophil to lymphocyte ratio) and SII (systemic immune index) are shown.
Statistical differences were assessed by Kruskal–Wallis test.
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uncertain. In our combined series of 152 surgically treated patients,
where the majority in our series (87%) were TNM I or TNM II, we
did not show significant differences in prognostic value for the two
widely reported ‘cut off’ values in either NLR or SII. The sensitivity
and specificity of these scores with early TNM stage disease is
therefore unlikely to be robust enough to influence treatment
decisions for individual patients at presentation. However, these
tools may yet have clinical value directing treatments within the
BCLC algorithm for those with more advanced disease. The
median NLR of 3.15, for example, distinguished significant survival
differences within patients classed as either BCLC B (n¼ 147 vs 87,
median survival 28.9 vs 15.9 months, P¼ 0.013, Kaplan–Meier) or
those classed as BCLC C (n¼ 248 vs 334, median survival 9.9 vs 3.6
months, Po0.001, Kaplan–Meier).
Considering the individual peripheral circulating cell counts and
survival analyses in the Newcastle cohort, the Hong Kong cohort
or the combined cohort, it was the neutrophil count that stood out
as being highly significantly and independently associated with
poorer survival. Notably, in the Hong Kong cohort where the
lymphocyte count was slightly lower, the lymphocyte count was
independently associated with poorer survival. In this distinct
geographical location the predominant underlying aetiology of
HCC is chronic viral hepatitis compared with ARLD or NAFLD in
Newcastle. Whether this is the cause of slightly lower lymphocytes
in this geographical location is uncertain, but it is interesting as the
data suggests that factors other than the cancer itself that suppress
the lymphocyte count may also contribute adversely to prognosis
in patients with HCC. The more consistent observation in our
study, however, independent of all other factors including
geographical location or underlying aetiology, was the association
of poorer survival with elevated neutrophils.
Neutrophils are not only the commonest white blood cells in the
circulation, they also have a shorter lifespan than the other cell
types. Neutrophils typically survive 5–90 h in the circulation with
an additional 1–2 days outside the circulation, compared with a
week or so for lymphocytes and 8–9 days for platelets. Thus, we
considered the possibility that these significant associations of
neutrophils were enhanced relative to other cells, owing to a lesser
impact of portal hypertension and hypersplenism - but the
persistence of significance in the absence of CLD was against this.
Neutrophils are the ‘first responders’ to insult or injury and it is
likely that they are one of the first immune cells to come into
contact with tumour cells. Our recent work in an animal model of
DEN-induced HCC highlights a potential role in promoting cancer
growth, as neutrophil depletion in advanced stage disease reduced
tumour burden (Wilson et al, 2015). Associated mechanisms are
unclear, but neutrophils are part of the spectrum of myeloid
suppressor cells (MDSCs), recognised as key regulators of the
tumour microenvironment, including the infiltration and pheno-
type of lymphocytes. The present study is on circulating cells rather
than the cells in the tumour microenvironment, and how
circulating neutrophil numbers reflect the tumour
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Figure 3. Inflammatory cells associations with PST. Newcastle and Hong Kong data sets combined associations with advancing Eastern
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microenvironment is unknown. Similarly, the contribution of
MDSCs to the circulating ‘neutrophil’ population is also unknown.
In the circulation there was no apparent relationship between
neutrophils and lymphocytes in the absence of CLD, although
lymphocyte subtypes were not assessed. It was notable that there
was a highly significant association between neutrophils and
platelets in the circulation. Similar correlations between the two,
with prognostic value, have been reported in other settings
(Ventura et al, 1987; Watt et al, 2015). More commonly reported
is the role of platelets in activating neutrophils. Immune and
inflammatory responses require neutrophils to migrate through
endothelial vasculature – a process dependent on their prior
interaction with activated platelets (Sreeramkumar et al, 2014). In
the circulation, platelets also contribute to the creation of
neutrophil extracellular traps, which serve to ensnare and kill
pathogens, but can inflict significant tissue damage (Kim and
Jenne, 2016). In the cancer setting, similar interactions with
circulating tumour cells may have roles in their elimination or
metastatic implantation (Mohme et al, 2017).
In summary, by studying two consecutive series of patients
totalling 1168, we have been able to validate the prognostic role of
both the NLR and SII in patients with more advanced stages of HCC.
Considering the individual cell types and their associations with
advanced disease, we have identified that circulating neutrophils –
rather than lymphocytes or platelets – are significantly and
independently associated with poorer prognosis and speculate that
neutrophils have roles in promoting immune mediated tumour
progression as well as the cancer cachexia syndrome. The relation-
ship between circulating neutrophils – either counts or subtypes –
with the tumour microenvironment has yet to be established.
However, we propose that neutrophil phenotype and function,
including interactions or regulatory roles with platelets or lympho-
cytes in the presence of cancer, are worthy of study and consideration
as clinically relevant therapeutic targets.
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Figure 4. Inflammatory cells associations with survival. Newcastle and Hong Kong data sets combined Kaplan–Meier survival curves for
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